Forecast 2023 Antidiabetics Market - Global Industry Analysis, Size, Share, Growth, Trends
"Antidiabetics
Market - Global Industry Analysis, Size, Share, Growth, Trends, &
Forecast 2015 - 2023"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
.
.
Description-
'
'
The
anti-diabetics market includes drugs, which are used for treatment of
diabetes mellitus and are also known as oral
hypoglycemic/antihyperglycemic agents. The anti-diabetics market has
grown tremendously in recent years with increasing prevalence of
diabetes mellitus. Thus, systemic therapies for diabetes have become
the focal point of attention due to the burgeoning diabetic
population size, with diabetes affecting middle age groups and
children across all income groups globally.
Get
Sample
Report
With TOC @
https://www.researchmoz.us/enquiry.php?type=S&repid=1353563
'
'
The
anti-diabetics market has been segmented based on type of drug class
into biguanides (metformin), sulfonylureas (glimepiride),
meglitinides (repaglinide), thiazolidinediones (pioglitazone),
dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and
?-glucosidase inhibitors (acarbose).
Among these drug classes, Biguanides act directly
against insulin resistance. Sulfonylureas (SUs) were the earliest
drug classes in the market for treatment of diabetes and have a
significant market presence. ?-glucosidase inhibitors delay
postprandial glucose absorption by hydrolysis of disaccharide is into
monosaccharide’s in the small intestine. Meglitinides are
prandial insulin releasers that stimulate rapid insulin secretion.
The thiazolidinediones are insulin-sensitizing drugs, which improve
whole-body insulin sensitivity through gene regulation. DPP-IV
inhibitors make a significant impact on glucose tolerance and make
lasting improvements in the health outcomes of diabetic patients.
Some of the major drivers and opportunities for
growth of this market include drug combinations of several agents
such as sitagliptin and metformin and other drug combinations that
are in different stages of clinical and pipeline development.
Increase in the prevalence of diabetes and new product launches by
major pharmaceutical companies re some of the key drivers for growth
in this market. In 2015, Boehringer Ingelheim GmbH launched two new
drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus
type II.
Some of the key opportunities for the
antidiabetics include a strong pipeline for antidiabetics and entry
of new players in the market, for instance, Novo Nordisk's diabetes
drug’s Tresiba, and Ryzodeg received FDA approval in September
2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for
anti-diabetic drugs, such as Linagliptin which is a dipeptidyl
peptidase (DPP) 4 inhibitor) for patients suffering from diabetes
mellitus type II and high cardiovascular risk.
However, despite the availability of numerous
branded antidiabetic drugs, many of these drugs have lost patent
protection. In the wake of huge pressures from government and
regulatory authorities, which have banned top selling drugs in
various countries, in order to promote generic drugs at lower costs
for diabetic patients. For instance, Mankind Pharma, launched
anti-diabeticDynaglipt (Teneligliptin) under the drug class DPP-4
inhibitors in November 2015 in India targeting the middle to low
income diabetic patient population.
As a result, the volume of antidiabetics is
expected to shift to first generation drugs and other generic drugs
in the market. Moreover, there is a huge unmet medical need for
antidiabetics that can treat multiple chronic disorderscoexisting
with diabetessuch as cardiovascular diseases, dyslipidemia,
hypertension etc. Another major restraint in the antidiabetics market
is reduction in the efficacy of drugs over a period and canlead to
other health complications.
Some of the major players in the market include
Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co.,
Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc.,
Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical
Industries Ltd.
This research report analyzes this market on the
basis of its market segments, major geographies, and current market
trends. This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends
in the market, industry growth drivers, and restraints. It provides
market projections for the coming years. It includes analysis of
recent developments in technology, Porter’s five force model
analysis and detailed profiles of top industry players. The report
also includes a review of micro and macro factors essential for the
existing market players and new entrants along with detailed value
chain analysis.
– Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note: Although care has been
taken to maintain the highest levels of accuracy in TMR’s reports,
recent market/vendor-specific changes may take time to reflect in the
analysis.
.
.
Report
Enquiry and Other Query @
https://www.researchmoz.us/enquiry.php?type=E&repid=1353563
Comments
Post a Comment